AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26591103 — intervention group
Group type: EXPERIMENTAL
Intervention: CRON diet
Number of subjects: 0
Study 26591103 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 0
Study 23446899 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 kiwifruit/d
Number of subjects: 36
Study 23446899 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 kiwifruit/d
Number of subjects: 36
Study 23446899 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 20691328 — intervention group
Group type: EXPERIMENTAL
Intervention: New cognitive behavioural treatment
Number of subjects: 150
Study 20691328 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy (leading alternative psychological treatment)
Number of subjects: 150
Study 20691328 — intervention group
Group type: COMPARATOR
Intervention: Guided self‐help (minimal intervention)
Number of subjects: 150
Study 20691328 — intervention group
Group type: COMPARATOR
Intervention: Behaviour therapy
Number of subjects: 150
Study 17918288 — intervention group
Group type: EXPERIMENTAL
Intervention: Left thoracic RT with EC CT
Number of subjects: 34
Study 17918288 — intervention group
Group type: COMPARATOR
Intervention: Right thoracic RT with EC CT
Number of subjects: 34
Study 15547564 — intervention group
Group type: COMPARATOR
Intervention: Head-on orientation
Number of subjects: 131
Study 15547564 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-on orientation
Number of subjects: 131
Study 11220440 — intervention group
Group type: EXPERIMENTAL
Intervention: In-group information processing
Number of subjects: 0
Study 11220440 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cognitive load
Number of subjects: 0
Study 11220440 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive load
Number of subjects: 0
Study 11220440 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiographic procedure
Number of subjects: 0
Study 11220440 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-congruent information attribution
Number of subjects: 0
Study 9475020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative 5-FU
Number of subjects: 33
Study 9475020 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative 5-FU
Number of subjects: 33
Study 9475020 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjunctive antimetabolites)
Number of subjects: 33
Study 7947383 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (20 mg once daily)
Number of subjects: 135
Study 7947383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 2828249 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with theophylline
Number of subjects: 10
Study 2828249 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with terbutaline
Number of subjects: 10
Study 2828249 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of theophylline and terbutaline
Number of subjects: 10
Study 2828249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31101039 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-initiated home-based sensori-motor training (SMT)
Number of subjects: 52
Study 31101039 — intervention group
Group type: COMPARATOR
Intervention: Functional exercise training (usual care)
Number of subjects: 52
Study 31101039 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 30509185 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific micronutrient combination
Number of subjects: 54
Study 30509185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 26691407 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity plyometric training
Number of subjects: 15
Study 26691407 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity plyometric training
Number of subjects: 15
Study 26691407 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity plyometric training
Number of subjects: 15
Study 26691407 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-intensity plyometric training
Number of subjects: 15
Study 24721460 — intervention group
Group type: EXPERIMENTAL
Intervention: P4 pain scale
Number of subjects: 156
Study 24721460 — intervention group
Group type: EXPERIMENTAL
Intervention: WOMAC-pain
Number of subjects: 156
Study 24721460 — intervention group
Group type: EXPERIMENTAL
Intervention: ICOAP
Number of subjects: 156
Study 24721460 — intervention group
Group type: EXPERIMENTAL
Intervention: WOMAC-function
Number of subjects: 156
Study 21937705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine/Gemcitabine doublet (VG arm: vinorelbine 25 mg/m2; gemcitabine 1000 mg/m2 on days 1 and 15)
Number of subjects: 148
Study 21937705 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (Cap arm: 1250 mg/m2 twice daily, on days 1-14)
Number of subjects: 148
Study 20853931 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT + P
Number of subjects: 206
Study 20853931 — intervention group
Group type: EXPERIMENTAL
Intervention: TSF + P
Number of subjects: 206
Study 20853931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 206
Study 20853931 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher attendance in both groups
Number of subjects: 206
Study 20853931 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial levels of depressive symptomology
Number of subjects: 206
Study 20853931 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment response
Number of subjects: 206
Study 17184890 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg)
Number of subjects: 10
Study 17184890 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg)
Number of subjects: 10
Study 17184890 — intervention group
Group type: COMPARATOR
Intervention: Methamphetamine (15 mg)
Number of subjects: 10
Study 17184890 — intervention group
Group type: COMPARATOR
Intervention: Methamphetamine (30 mg)
Number of subjects: 10
Study 16084254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antibiotic susceptibility testing (MCBT)
Number of subjects: 251
Study 16084254 — intervention group
Group type: COMPARATOR
Intervention: Conventional culture and sensitivity testing
Number of subjects: 251
Study 12898820 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stage of disease (before treatment)
Number of subjects: 9
Study 12898820 — intervention group
Group type: EXPERIMENTAL
Intervention: After clearing of skin lesions (after effective treatment)
Number of subjects: 9
Study 10511362 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day of elemental calcium
Number of subjects: 256
Study 10511362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 7486112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside treatment
Number of subjects: 24
Study 7486112 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 1941777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraconservative sealed composite restorations (CompS/C)
Number of subjects: 0
Study 1941777 — intervention group
Group type: COMPARATOR
Intervention: Ultraconservative sealed amalgam restorations (AGS)
Number of subjects: 0
Study 7010990 — intervention group
Group type: EXPERIMENTAL
Intervention: Human thromboplastin (British Comparative Thromboplastin)
Number of subjects: 0
Study 7010990 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit thromboplastin (Simplastin Automated)
Number of subjects: 0
Study 7010990 — intervention group
Group type: COMPARATOR
Intervention: Bovine thromboplastin (Thrombotest)
Number of subjects: 0
Study 31116188 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mm-long and 4-mm-wide implants
Number of subjects: 40
Study 31116188 — intervention group
Group type: COMPARATOR
Intervention: Implants at least 10-mm long in augmented bone
Number of subjects: 40
Study 28318845 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect‐oriented communication
Number of subjects: 293
Study 28318845 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expectations
Number of subjects: 293
Study 28318845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of positive affect‐oriented communication and positive expectation
Number of subjects: 293
Study 25635925 — intervention group
Group type: EXPERIMENTAL
Intervention: Music combined with vibration on acupuncture points
Number of subjects: 120
Study 25635925 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimuli on acupuncture points
Number of subjects: 120
Study 25635925 — intervention group
Group type: EXPERIMENTAL
Intervention: Music only (Bach's compositions)
Number of subjects: 120
Study 25635925 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 120
Study 25635925 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete group (music + vibration + binaural beats)
Number of subjects: 120
Study 24167605 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent antenatal Common Mental Disorders (CMD) defined as EPDS-V score ≥ 4 in both W1 and W2
Number of subjects: 378
Study 24167605 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of Iron Deficiency Anaemia (IDA) in the third trimester
Number of subjects: 378
Study 24167605 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to take iron supplements
Number of subjects: 378
Study 24167605 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher household wealth index
Number of subjects: 378
Study 24167605 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of time that iron supplements had been taken
Number of subjects: 378
Study 24167605 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pregnancy IDA
Number of subjects: 378
Study 24167605 — intervention group
Group type: EXPERIMENTAL
Intervention: Being multi-parous
Number of subjects: 378
Study 21161116 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (4 contractions of 45 seconds each at 30% of maximal grip strength for 5 days)
Number of subjects: 18
Study 21161116 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 minutes of sitting without exercising for 5 days)
Number of subjects: 18
Study 19194676 — intervention group
Group type: EXPERIMENTAL
Intervention: Camouflage orthodontics (premolar extraction)
Number of subjects: 60
Study 19194676 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed functional orthopedic appliance
Number of subjects: 60
Study 19194676 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthognathic surgery (bilateral sagittal split osteotomy)
Number of subjects: 60
Study 17763203 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg bd)
Number of subjects: 37
Study 17763203 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5 mg bd)
Number of subjects: 37
Study 17763203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 15199080 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (MJ)
Number of subjects: 0
Study 15199080 — intervention group
Group type: COMPARATOR
Intervention: Placebo marijuana (MJ)
Number of subjects: 0
Study 11398877 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-cisplatin-etoposide (TEP) regimen
Number of subjects: 133
Study 11398877 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-etoposide (EP) regimen
Number of subjects: 133
Study 9508295 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR assay for Bordetella pertussis
Number of subjects: 2442
Study 9508295 — intervention group
Group type: COMPARATOR
Intervention: Cultures for Bordetella pertussis
Number of subjects: 2442
Study 9508295 — intervention group
Group type: EXPERIMENTAL
Intervention: Parapertussis PCR using primers BPPA and BPPZ
Number of subjects: 2442
Study 7659480 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP
Number of subjects: 2342
Study 7659480 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP
Number of subjects: 2342
Study 7659480 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP and DTaP
Number of subjects: 2342
Study 2396471 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x S (three doses of suspension-formulated vaccine)
Number of subjects: 4
Study 2396471 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x E (three doses of vaccine in enteric-coated capsules)
Number of subjects: 4
Study 2396471 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x S (two doses of suspension-formulated vaccine)
Number of subjects: 4
Study 2396471 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x S (one dose of suspension-formulated vaccine)
Number of subjects: 4
Study 93180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide
Number of subjects: 0
Study 30138543 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid (20 mg prednisolone)
Number of subjects: 9
Study 30138543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mg Avicel)
Number of subjects: 9
Study 26969581 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training to pleasant (ATP) stimuli
Number of subjects: 0
Study 26969581 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (PC) condition
Number of subjects: 0
Study 26462799 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion board only (arm 1)
Number of subjects: 0
Study 26462799 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion board plus psychoeducation (arm 2)
Number of subjects: 0
Study 26462799 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion board, psychoeducation plus cognitive behavioural therapy-based tools (arm 3)
Number of subjects: 0
Study 22463922 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR236553 50 mg Q2W
Number of subjects: 183
Study 22463922 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR236553 100 mg Q2W
Number of subjects: 183
Study 22463922 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR236553 150 mg Q2W
Number of subjects: 183
Study 22463922 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR236553 200 mg Q4W
Number of subjects: 183
Study 22463922 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR236553 300 mg Q4W
Number of subjects: 183
Study 22463922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 22463922 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR236553
Number of subjects: 183
Study 20934557 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg intravenous bolus of potassium canrenoate followed by a daily 25-mg dose of spironolactone for 6 months
Number of subjects: 1600
Study 20934557 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 1600
Study 18074183 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilation
Number of subjects: 31
Study 18074183 — intervention group
Group type: COMPARATOR
Intervention: Surgical controls
Number of subjects: 31
Study 18074183 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 31
Study 15725087 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive immunotherapy
Number of subjects: 65
Study 12783152 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 16
Study 12783152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10839223 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet Suits (WS)
Number of subjects: 19
Study 10839223 — intervention group
Group type: COMPARATOR
Intervention: No Wet Suits (Control)
Number of subjects: 19
Study 9119352 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine
Number of subjects: 140
Study 9119352 — intervention group
Group type: COMPARATOR
Intervention: Chlormezanone
Number of subjects: 140
Study 9119352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 2062631 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 6501905 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified trivalent sub‐unit influenza vaccine
Number of subjects: 69
Study 6501905 — intervention group
Group type: EXPERIMENTAL
Intervention: 14‐valent pneumococcal vaccine
Number of subjects: 69
Study 6501905 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 69
Study 30281866 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM sublingual tablets (300 index of reactivity) once daily for 52 weeks
Number of subjects: 438
Study 30281866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study 30143003 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical medication review (CMR) focused on patients' preferences, personal goals, and health-related complaints.
Number of subjects: 630
Study 30143003 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 630
Study 30143003 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes include healthcare utilisation, number and type of drug changes, number and type of health-related goals, scores on goal attainment scale (GAS), and number and type of drug-related problems (DRPs) and interventions.
Number of subjects: 630
Study 26414074 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection speed of 0.3 ml/s (15 seconds)
Number of subjects: 36
Study 26414074 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection speed of 0.15 ml/s (30 seconds)
Number of subjects: 36
Study 26414074 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection speed of 0.1 ml/s (45 seconds)
Number of subjects: 36
Study 24899160 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/d lutein (low-dose)
Number of subjects: 89
Study 24899160 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/d lutein (high-dose)
Number of subjects: 89
Study 24899160 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/d lutein (placebo)
Number of subjects: 89
Study 22992291 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (74 patients) that viewed former self-reported PROMs scores and discussed the joint fitness programme.
Number of subjects: 147
Study 22992291 — intervention group
Group type: COMPARATOR
Intervention: Control group (73 patients) that continued treatment based on recorded PROMs and clinical assessment.
Number of subjects: 147
Study 20405788 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum A
Number of subjects: 10
Study 20405788 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum B
Number of subjects: 10
Study 20405788 — intervention group
Group type: COMPARATOR
Intervention: Cotton ball
Number of subjects: 10
Study 20405788 — intervention group
Group type: COMPARATOR
Intervention: Parafilm M
Number of subjects: 10
Study 18254326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized Pulmicort respimat
Number of subjects: 44
Study 18254326 — intervention group
Group type: COMPARATOR
Intervention: Budesonide aqueous nasal spray
Number of subjects: 44
Study 17547948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingualized posterior occlusal forms
Number of subjects: 45
Study 17547948 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic posterior occlusal forms
Number of subjects: 45
Study 17547948 — intervention group
Group type: COMPARATOR
Intervention: 0-degree posterior occlusal forms
Number of subjects: 45
Study 17547948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingualized vs Anatomic posterior occlusal forms
Number of subjects: 45
Study 15452011 — intervention group
Group type: EXPERIMENTAL
Intervention: Private sector strategies (training, regulation, incentives)
Number of subjects: 71
Study 15452011 — intervention group
Group type: EXPERIMENTAL
Intervention: Training private providers
Number of subjects: 71
Study 15452011 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of strategies
Number of subjects: 71
Study 15452011 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust designs (randomized controlled trials)
Number of subjects: 71
Study 15452011 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term effects
Number of subjects: 71
Study 10624997 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 40
Study 10624997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9186385 — intervention group
Group type: COMPARATOR
Intervention: DTP-IPV vaccine alone (n = 43)
Number of subjects: 84
Study 9186385 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-IPV vaccine with PVRV (n = 41)
Number of subjects: 84
Study 8233146 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral laxatives
Number of subjects: 136
Study 8233146 — intervention group
Group type: COMPARATOR
Intervention: Conditional rectal cathartics
Number of subjects: 136
Study 3887636 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE‐Heparin
Number of subjects: 105
Study 3887636 — intervention group
Group type: COMPARATOR
Intervention: Impedance plethysmography (IPG)
Number of subjects: 105
Study 31557061 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group (EAG)
Number of subjects: 0
Study 31557061 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group (AG)
Number of subjects: 0
Study 29549968 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (n=11)
Number of subjects: 19
Study 29549968 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=8)
Number of subjects: 19
Study 28257727 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75-mm retainer
Number of subjects: 80
Study 28257727 — intervention group
Group type: COMPARATOR
Intervention: 1.00-mm retainer
Number of subjects: 80
Study 25158943 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM peeling group (30 eyes)
Number of subjects: 60
Study 25158943 — intervention group
Group type: COMPARATOR
Intervention: ILM not peeling group (30 eyes)
Number of subjects: 60
Study 25608550 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirituality Promotion Program (SPP) for young nurses, completed over 8 weeks.
Number of subjects: 41
Study 21511473 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure for two hours for four days after extubation.
Number of subjects: 0
Study 21511473 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bright light exposure).
Number of subjects: 0
Study 21511473 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure.
Number of subjects: 0
Study 19825060 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw-Thrust-Device
Number of subjects: 50